Terminated PHASE1 INTERVENTIONAL 1-arm NCT00492271

First Time in Man Trial for Friulimicin B

A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single (Part A) and Multiple (Part B) Intravenous Doses of Friulimicin B in Healthy Subjects

Sponsor: MerLion Pharmaceuticals GmbH

Conditions Community Acquired Pneumonia Staphylococcal Skin Infections

Interventions Friulimicin B

Updated 5 times since 2017 Last updated: Jul 22, 2008 Started: Jun 30, 2007 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unfavourable Pharmakokinetics

A PHASE1 clinical study on Community Acquired Pneumonia and Staphylococcal Skin Infections, this trial is terminated or withdrawn. The trial is conducted by MerLion Pharmaceuticals GmbH and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MerLion Pharmaceuticals GmbH

Data source: MerLion Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland